• Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson sold 8,000 common shares on Sept. 8 at USD 21.57.
• She exercised stock options for 4,000 shares the same day at USD 4.3.
• Directly held common shares fell to 158,844.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-387381), on September 10, 2026, and is solely responsible for the information contained therein.